Yersinia pestis infection cost-effectiveness of therapy: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
m (Changes made per Mahshid's request) |
||
Line 12: | Line 12: | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Disease]] | [[Category:Disease]] |
Latest revision as of 19:31, 18 September 2017
Yersinia pestis infection Microchapters |
Differentiating Yersinia Pestis Infection from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Yersinia pestis infection cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Yersinia pestis infection cost-effectiveness of therapy |
FDA on Yersinia pestis infection cost-effectiveness of therapy |
CDC on Yersinia pestis infection cost-effectiveness of therapy |
Yersinia pestis infection cost-effectiveness of therapy in the news |
Blogs on Yersinia pestis infection cost-effectiveness of therapy |
Risk calculators and risk factors for Yersinia pestis infection cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Without treatment, the plague can cause serious illness or death. With adequate antibiotic treatment the mortality rate is about 8-10%.[1] Therefore the treatment of plague may be considered cost-effective.